Extract

Eligible subjects will be randomly assigned to one of three dose regimens of oral R115866 or placebo for the treatment of severe plaque psoriasis for 12 twelve weeks. The safety and efficacy of R115866 will be evaluated during the treatment period and the 8-week post treatment follow-up period.

Inclusion criteria

• Psoriasis

Country

• Germany
• Ireland
• Netherlands
• Russian Federation
• United Kingdom

Links

• ictrp
• nct